Research & Development
Academic Report
【Conference presentation】Highly specific plasma β-amyloid assays on the fully automated platform predict brain β-amyloid pathology determined by a Centiloid threshold of amyloid PET
| Presented by: | Kazuto Yamashita1), Masahiro Miura1), Shunsuke Watanabe1), Kengo Ishiki1), Yuji Arimatsu2), Junko Kawahira3), Toshiko Kubo3), Katsutaka Sasaki4), Takayuki Arai4), Kei Hagino2), Yasuhiro Irino1), Kota Nagai5), David Verbel6), Akihiko Koyama7), Shobha Dhadda8), Hayato Niiro9), Shigeki Iwanaga1), Toshiyuki Sato1), Tomokazu Yoshida10), Atsushi Iwata11) 1) Central Research Laboratories, Sysmex Corporation, Kobe, Japan 2) Business Incubation Division, Sysmex Corporation, Kobe, Japan 3) Reagent Engineering Division, Sysmex Corporation, Kobe, Japan 4) Sysmex R&D Center Americas, Inc., Mundelein, Illinois, USA 5) Japan and Asia Clinical Development Department, Eisai Co., Ltd., Japan 6) Biostatistics, Eisai Inc., Nutley, NJ, USA 7) Translational Science, Eisai Inc., Nutley, NJ, USA 8) Biostatistics and Clinical Development Operations, Eisai Inc., Nutley, NJ, USA 9) Medical Affairs Division, Sysmex Corporation, Kobe, Japan 10) Sysmex Corporation, Kobe, Japan 11) Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of gerontology, Tokyo, Japan |
| Academic conference: | Alzheimer's Association International Conference®: AAIC2022 |
| Presentation Date: | August 3, 2022 |
| Session: | Developing : Poster（P4-21 / #68727） |
| Notes: | Joint announcement with Sysmex Corporation, Eisai Co., Ltd., and Tokyo Metropolitan Geriatric Hospital and Institute of gerontology. |
- Information contained in the academic report is current as of the date of the announcement,
but may be subject to change without prior notice.